On July 30, 2026, in Florham Park, N.J., Cellectar Biosciences, Inc. (NASDAQ: CLRB), a company specializing in cancer drug development, shared plans to disclose its financial performance for the second quarter concluding on June 30, 2026. The corporate update, which will include this financial data, is scheduled for August 13, 2026, at 8:30 a.m. Eastern Time. Cellectar Biosciences, Inc. is known for its late-stage clinical biopharmaceutical work.